HSPG2 and Alzheimer disease: Amyloid that accumulates within the vasculature, CAA, and brain parenchyma, forms plaques (AD) that disrupt the distribution of perlecan (Table 3) [147,148,149], decreases the ability of SMC to bind perlecan [150], and contributes to vascular wall weakening [147].